Celldex Therapeutics
CLDX
159 hedge funds and large institutions have $1.35B invested in Celldex Therapeutics in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 58 increasing their positions, 38 reducing their positions, and 24 closing their positions.
112% more call options, than puts
Call options by funds: $21.5M | Put options by funds: $10.1M
53% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 38
5% more capital invested
Capital invested by funds: $1.28B → $1.35B (+$66.3M)
2.31% more ownership
Funds ownership: 102.57% → 104.89% (+2.3%)
1% more funds holding
Funds holding: 157 → 159 (+2)
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$39.1M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$26.8M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$24.6M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$19.4M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$63M |
| 2 |
VA
VR Adviser
New York
|
-$24.2M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$11M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.8M |
| 5 |
Morgan Stanley
New York
|
-$8.54M |
CLDX Hedge Fund Activity: Q3 2022 in Review
159 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2022, worth a combined $1.35B — up 5.2% from $1.28B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CLDX positions and 24 closed out — a net gain of 2 holders — while 58 added to existing stakes and 38 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $39.1M. The largest seller was Viking Global Investors, exiting entirely with an estimated $63M sold.
- 159 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2022, up from 157 in Q2 2022.
- Funds reported $1.35B of Celldex Therapeutics stock for Q3 2022, up 5.2% quarter-over-quarter.
- 26 funds opened new Celldex Therapeutics positions in Q3 2022 and 24 closed out, a net change of +2 holders.
- The largest Celldex Therapeutics buyer in Q3 2022 was Jennison Associates, an estimated $39.1M added.
- The largest Celldex Therapeutics seller in Q3 2022 was Viking Global Investors, an estimated $63M sold.
Based on aggregated 13F filings for Q3 2022.